Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Tenaya Therapeutics $52.5 million units offering
The units comprise common stock and warrants
Denali Therapeutics $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Haleon $3 billion secondary placing of ordinary shares
The private placement included 700,000,000 ordinary shares
AbbVie $4 billion senior notes offering
The investment-grade notes are due 2028, 2030, 2035 and 2055
Solid Biosciences $200 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
NeuroPace $74.75 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market
BioVersys CHF 80 million IPO and concurrent private placement
We advised AMR Action Fund on its investment in BioVersys